TABLE 1

IC50 values determined with 30-minute preincubation and inhibition characteristics for the alkaloids organized according to the isoquinoline alkaloid subgroups.

The methylenedioxyphenyl (MDP) moiety is shown in 1 (protopine) inside the circle.

No.Compound (Stereochemistry)StructureShifted IC50a (95% CIb) (µM)IC50-fold Shift or TDIc
ProtopinesEmbedded Image
1ProtopineEmbedded Image1.8 (1.1–2.8)1.5
2HunnemannineEmbedded Image79 (63–101)N.D.
3CryptopineEmbedded Image0.66 (0.53–0.82)4.9
4AllocryptopineEmbedded Image76 (37–157)1.9
5Corycavidine (13S)Embedded Image15 (6.5–36)6.3
6Corycavamine (13R)Embedded Image0.19 (0.13–0.27)6.4
7Dihydrocryptopined(racemic)Embedded Image0.35 (0.23–0.53)3.5
8Dihydroprotopined(racemic)Embedded Image0.11 (0.078–0.16)2.7
92,3-Dimethoxy-7-methyl-9,10-dimethoxy-5,6,7,8,13,14-hexahydrodibenzo [d,h,] azecineEmbedded Image23 (10–53)>4.3
AporphinesEmbedded Image
10Apomorphine (R)Embedded Image7.8 (4.7–13)2.3
11Bulbocapninemethyletherd (S)Embedded Image61 (48–77)1.5
12Bulbocapnine (S)Embedded Image8.4 (5.7–12)2.1
13Isocorydine (S)Embedded Image33 (20–54)1.9
14Corydine (S)Embedded Image91 (51–162)TDI
15Nantenine (S)Embedded Image3.5 (2.4–5.2)N.D.
SpirobenzylisoquinolinesEmbedded Image
16Parfumine (S)Embedded Image6.3 (3.7–11)2.4
PhthalideisoquinolinesEmbedded Image
17Capnoidine (1R, 9R)Embedded Image0.47 (0.37–0.60)TDI
18Bicuculline (1S, 9R)Embedded Image150 (91–246)9.5
19Noscapine (3S, 5R)Embedded Image0.20 (0.13–0.30)5.0
ProtoberberinesEmbedded Image
20Canadined(racemic)Embedded Image0.29 (0.20–0.47)7.6
21Nandinine (racemic)Embedded Image0.37 (0.30–0.47)10.1
22Corydaline (13S, 13aR)Embedded Image3.1 (2.0–4.8)TDI
23Tetrahydropalmatine (13aR)Embedded Image7.0 (6.0–8.1)3.0
24Corypalmine (13aS)Embedded Image8.9 (0.1–18.5)N.D.
25Stylopined(racemic)Embedded Image0.13 (0.083–0.19)4.5
26Thalictricavine (13S, 13aR)Embedded Image2.4 (1.7–3.3)4.5
27Isocorybulbine (13S, 13aR)Embedded Image210 (141–324)N.D.
28Corybulbine (13S, 13aR)Embedded Image5.4 (3.6–8.1)3.4
29Scoulerine (13aS)Embedded Image22 (13–38)3.3
30Mecambridine (13aS)Embedded Image21 (15–31)4.7
312,3,10,11-Tetramethoxyberbinee(racemic)Embedded Image190 (141–258)N.D.
328-Ethyl-2,3,10,11-tetramethoxyberbinee (racemic)Embedded Image Embedded Image31 (23–43)4.8
338-Methyl-2,3,10,11-tetramethoxyberbinee (racemic)130 (97–176)N.D.
348-Methyl-2,3,10,11-tetraethoxyberbinee (racemic)Embedded Image59 (39–87)N.D.
352,3-Dimethoxy-10,11-methylenedioxyberbinee (racemic)Embedded Image2.3 (1.7–3.1)3.8
362,3-Dimethoxy-9,10-methylenedioxyberbinee (racemic)Embedded Image5.0 (4.2–6.0)4.5
373,10,11-Trimethoxyberbinee (racemic)Embedded Image25 (11–58)TDI
383-Methoxyberbinee(racemic)Embedded Image2.4 (1.2–5.0)TDI
392,3-Dimethoxyberbinee(racemic)Embedded Image40 (28–56)TDI
403-Hydroxyberbinee(racemic)Embedded Image14 (10–18)>7
412,3,9,10-Tetrahydroxyberbine(racemic)Embedded Image19 (12–30)1.5
423,10-Dimethoxy-11-hydroxyberbinee(racemic)Embedded Image11 (3.6–35)>8.9
Embedded Image
43Berberine hemisulfate150 (42–298)2.3
44PalmatineEmbedded Image120 (84–185)2.9
Others
45Chelidonine (5bR, 6S, 12bS)Embedded Image1.4 (1.1–1.7)8.4
46Papaverine hydrochlorideEmbedded Image2.2 (1.6–3.2)1.6
47Sinomenine (9aR, 13aS, 14aS)Embedded Image55 (37–83)11.5
48Norlaudanosine hydrochloride (racemic)Embedded Image13 (11–15)3.3
49Pavine hydrochloride (racemic)Embedded Image82 (70–97)3.9
  • N.D., not determined.

  • a Determined with 30-minute preincubation.

  • b Confidence intervals.

  • c Time-dependent inhibition by progress curve analysis.

  • d Semisynthetic.

  • e Synthetic.